BASKING RIDGE, N.J. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial of non-invasive
ROCKAWAY, N.J. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal
BASKING RIDGE, N.J. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patients with workers’
ROCKAWAY, N.J. , March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medical Officer, Dr. Peter Staats , will keynote the Fifth Annual Bioelectronic Medicine Forum on April
ROCKAWAY, NJ , July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats , is to receive a Lifetime Achievement Award at the American Society
Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis BASKING RIDGE, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic
ROCKAWAY, N.J. , April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Teijin Limited (Teijin), a global conglomerate based in Japan offering advanced solutions
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022 Revenue growth of approximately 57% over full-year 2021 Launched two new brands; TAC-STIM ™ under the Air Force BOOST program and Truvaga ™ wellness product for stress,
Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting BASKING RIDGE, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the FDA has issued an Emergency Use Authorization (EUA)
Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities Company to host conference call and webcast today, May 14 , at 4:30pm ET BASKING RIDGE, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic